Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1147) 1147
Publication (126) 126
Conference Proceeding (13) 13
Book Chapter (12) 12
Patent (11) 11
Book Review (4) 4
Book / eBook (3) 3
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (392) 392
hematology (367) 367
transplantation (353) 353
index medicus (275) 275
middle aged (253) 253
female (242) 242
adult (234) 234
male (234) 234
hematology, oncology and palliative medicine (210) 210
aged (183) 183
immunology (153) 153
hematopoietic stem cells (147) 147
article (139) 139
oncology (136) 136
stem cells (130) 130
transplantation, homologous (129) 129
bone-marrow-transplantation (123) 123
treatment outcome (120) 120
hematopoietic stem cell transplantation (100) 100
hematopoietic stem cell transplantation - methods (96) 96
adolescent (83) 83
chemotherapy (78) 78
bone marrow (77) 77
cancer (76) 76
disease-free survival (76) 76
care and treatment (74) 74
multiple myeloma (74) 74
transplantation conditioning - methods (74) 74
therapy (72) 72
versus-host-disease (71) 71
retrospective studies (70) 70
survival analysis (70) 70
recurrence (66) 66
stem-cell transplantation (66) 66
hematopoietic stem cell transplantation - adverse effects (65) 65
leukemia (65) 65
multiple myeloma - therapy (60) 60
analysis (58) 58
antineoplastic combined chemotherapy protocols - therapeutic use (58) 58
transplantation, autologous (58) 58
young adult (56) 56
prognosis (54) 54
acute myeloid-leukemia (53) 53
combined modality therapy (52) 52
risk factors (49) 49
survival rate (49) 49
child (46) 46
graft vs host disease - prevention & control (46) 46
relapse (46) 46
stem cell transplantation (46) 46
transplantation conditioning (46) 46
survival (45) 45
remission induction (44) 44
bone-marrow transplantation (43) 43
mortality (43) 43
patient outcomes (41) 41
t cells (41) 41
hematologic neoplasms - therapy (40) 40
bone marrow transplantation (39) 39
child, preschool (39) 39
chronic myelogenous leukemia (39) 39
research (38) 38
surgical procedures, operative (37) 37
antineoplastic agents - therapeutic use (36) 36
abridged index medicus (34) 34
hematologic malignancies (34) 34
allogeneic transplantation (33) 33
follow-up studies (32) 32
health aspects (32) 32
hemic and lymphatic diseases (32) 32
acute myelogenous leukemia (31) 31
autologous transplantation (30) 30
hematopoietic stem cell transplantation - mortality (30) 30
chronic myeloid-leukemia (29) 29
leukemia, myelogenous, chronic, bcr-abl positive - therapy (29) 29
bone-marrow (28) 28
multiple myeloma - drug therapy (28) 28
multiple myeloma - mortality (28) 28
myelodysplastic syndromes - therapy (28) 28
prospective studies (28) 28
blood (27) 27
leukemia, myeloid, acute - therapy (27) 27
melphalan (27) 27
total-body irradiation (27) 27
high-dose chemotherapy (26) 26
unrelated donors (26) 26
adults (25) 25
bortezomib (25) 25
medical research (25) 25
outcomes (25) 25
prevention (25) 25
vidarabine - analogs & derivatives (25) 25
time factors (24) 24
epidemiology (23) 23
graft vs host disease - etiology (23) 23
immunotherapy (23) 23
infant (23) 23
medicine, experimental (23) 23
minimal residual disease (23) 23
multiple-myeloma (23) 23
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1166) 1166
French (4) 4
German (4) 4
Spanish (4) 4
Portuguese (3) 3
Chinese (2) 2
Korean (2) 2
Catalan (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Setting Up a CAR T Program Ins and Outs
by Giralt, Sergio
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 09/2019, Volume 19, pp. S28 - S28
cellular therapy | CAR T cells | Chimeric Antigen Receptor (CAR) T cell therapies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Non-myeloablative stem cell transplantation
: NST
by Giralt, Sergio and Slavin, Shimon
2000, New frontiers in cancer therapy, ISBN 1903557003, xv, 159
Hematological oncology | Transplantation | Hematopoietic stem cells
Book
Details down arrow
3. Full Text Busulfan-based conditioning regimens: not all partners are equal
by Giralt, Sergio
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 15, pp. 1448 - 1449
Hematology, Oncology and Palliative Medicine | LEUKEMIA | ONCOLOGY | STEM-CELL TRANSPLANTATION | CYCLOPHOSPHAMIDE | FLUDARABINE | Cyclophosphamide - administration & dosage | Humans | Hematopoietic Stem Cell Transplantation | Induction Chemotherapy | Male | Vidarabine - analogs & derivatives | Antineoplastic Agents - administration & dosage | Busulfan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Leukemia, Myeloid, Acute - drug therapy | Female | Leukemia, Myeloid, Acute - surgery | Transplantation Conditioning | Busulfan
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents
by Asher A. Chanan-Khan and Sergio Giralt
Journal of Clinical Oncology, ISSN 0732-183X, 05/2010, Volume 28, Issue 15, pp. 2612 - 2624
The goal of treatment for multiple myeloma (MM) is to improve patients' long-term outcomes. One important factor that has been associated with prolonged... 
PEGYLATED LIPOSOMAL DOXORUBICIN | SINGLE-CENTER EXPERIENCE | POLYMERASE-CHAIN-REACTION | ONCOLOGY | HIGH-DOSE THERAPY | PROGRESSION-FREE SURVIVAL | NEWLY-DIAGNOSED MYELOMA | PREDNISONE PLUS THALIDOMIDE | STEM-CELL TRANSPLANTATION | MINIMAL RESIDUAL DISEASE | COOPERATIVE-ONCOLOGY-GROUP | Disease-Free Survival | Treatment Outcome | Multiple Myeloma - drug therapy | Antineoplastic Agents - therapeutic use | Humans
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug
by Bach, Peter B and Giralt, Sergio A and Saltz, Leonard B
JAMA, ISSN 0098-7484, 11/2017, Volume 318, Issue 19, pp. 1861 - 1862
Approval of the drug tisagenledeucel (Kymriah; Novartis) by the US Food and Drug Administration (FDA) for the treatment of pediatric and young adult acute... 
MEDICINE, GENERAL & INTERNAL | Regulatory agencies | Reminder | Acute lymphatic leukemia | Revenues | Leukemia | Norms | Oncology | FDA approval | Lymphatic leukemia | Cancer therapies | Patients | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text 200 mg/m 2 melphalan-the gold standard for multiple myeloma
by Giralt, Sergio
Nature Reviews Clinical Oncology, ISSN 1759-4774, 09/2010, Volume 7, Issue 9, pp. 490 - 491
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial
by Krishnan, Amrita, MD and Pasquini, Marcelo C, MD and Logan, Brent, PhD and Stadtmauer, Edward A, Prof and Vesole, David H, Prof and Alyea, Edwin, MD and Antin, Joseph H, Prof and Comenzo, Raymond, Prof and Goodman, Stacey, Prof and Hari, Parameswaran, MD and Laport, Ginna, MD and Qazilbash, Muzaffar H, MD and Rowley, Scott, Prof and Sahebi, Firoozeh, MD and Somlo, George, MD and Vogl, Dan T, MD and Weisdorf, Daniel, Prof and Ewell, Marian, ScD and Wu, Juan, MS and Geller, Nancy L, PhD and Horowitz, Mary M, MD and Giralt, Sergio, Prof and Maloney, David G, Prof and Blood Marrow Transplant Clinical and Blood Marrow Transplant Clinical Trials Network (BMT CTN)
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 13, pp. 1195 - 1203
Summary Background Autologous haemopoietic stem-cell transplantation (HSCT) improves survival in patients with multiple myeloma, but disease progression... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | MAINTENANCE | DEXAMETHASONE | SINGLE | ONCOLOGY | BONE-MARROW-TRANSPLANTATION | NEWLY-DIAGNOSED MYELOMA | CLINICAL-TRIALS | THALIDOMIDE | CHEMOTHERAPY | Myeloablative Agonists - therapeutic use | Multiple Myeloma - mortality | United States | Humans | Middle Aged | Male | Transplantation, Autologous | Hematopoietic Stem Cell Transplantation - mortality | Transplantation, Homologous | Young Adult | Multiple Myeloma - drug therapy | Time Factors | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Multiple Myeloma - surgery | Dexamethasone - administration & dosage | Multiple Myeloma - diagnosis | Risk Assessment | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Graft vs Tumor Effect | Survival Rate | Treatment Outcome | Thalidomide - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Care and treatment | Oncology, Experimental | Multiple myeloma | Stem cells | Transplantation | Research | Universities and colleges | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text 200 mg/m2 melphalan—the gold standard for multiple myeloma
by Giralt, Sergio
Nature Reviews Clinical Oncology, ISSN 1759-4774, 09/2010, Volume 7, Issue 9, pp. 490 - 491
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Transplantation remains significantly underused
by Giralt, Sergio
Clinical advances in hematology & oncology : H&O, ISSN 1543-0790, 05/2014, Volume 12, Issue 5, p. 319, 322
Multiple Myeloma - drug therapy | Multiple Myeloma - mortality | Humans | Hematopoietic Stem Cell Transplantation | Antineoplastic Agents - therapeutic use | Combined Modality Therapy | Multiple Myeloma - surgery
Journal Article
Details down arrow
10. Full Text Graft-versus-host disease: Have we solved the problem?
by Giralt, Sergio
Journal of Clinical Oncology, ISSN 0732-183X, 09/2012, Volume 30, Issue 26, pp. 3160 - 3161
TRIAL | SURVIVAL | PROPHYLAXIS | HEMATOPOIETIC-CELL TRANSPLANTATION | ONCOLOGY | BONE-MARROW-TRANSPLANTATION | LEUKEMIA | BLOOD | Hematologic Neoplasms - therapy | Antigens, CD34 - metabolism | Bortezomib | Humans | Immunosuppressive Agents - therapeutic use | Pyrazines - administration & dosage | Male | T-Lymphocyte Subsets - metabolism | Hematopoietic Stem Cell Transplantation - adverse effects | Female | Graft vs Host Disease - prevention & control | Boronic Acids - administration & dosage | Hematopoietic Stem Cell Transplantation - methods | Lymphocyte Depletion - methods | Leukemia, Myeloid, Acute - therapy | Siblings
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Stem cell transplantation for multiple myeloma: current and future status
by Giralt, Sergio
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, ISSN 1520-4391, 2011, Volume 2011, pp. 191 - 196
High-dose melphalan with autologous stem cell support has been an integral part of myeloma therapy for more than 25 years, either as salvage therapy or as... 
STANDARD CHEMOTHERAPY | MAINTENANCE | PLUS DEXAMETHASONE | BONE-MARROW-TRANSPLANTATION | HIGH-DOSE THERAPY | CONSOLIDATION THERAPY | RANDOMIZED-TRIAL | THALIDOMIDE | BORTEZOMIB | HEMATOLOGY | MELPHALAN | EDUCATION, SCIENTIFIC DISCIPLINES
Journal Article
Details down arrow
12. To transplant or not to transplant in multiple Myeloma: Transplantation remains significantly underused
by Giralt, Sergio
Clinical Advances in Hematology and Oncology, ISSN 1543-0790, 2014, Volume 12, Issue 5, pp. 319 - 323
Journal Article
Details down arrow
13. Full Text In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs
by Tefferi, Ayalew, MD and Kantarjian, Hagop, MD and Rajkumar, S. Vincent, MD and Baker, Lawrence H., DO and Abkowitz, Jan L., MD and Adamson, John W., MD and Advani, Ranjana Hira, MD and Allison, James, MD and Antman, Karen H., MD and Bast, Robert C., MD and Bennett, John M., MD and Benz, Edward J., MD and Berliner, Nancy, MD and Bertino, Joseph, MD and Bhatia, Ravi, MD and Bhatia, Smita, MD and Bhojwani, Deepa, MD and Blanke, Charles D., MD and Bloomfield, Clara D., MD and Bosserman, Linda, MD and Broxmeyer, Hal E., PhD and Byrd, John C., MD and Cabanillas, Fernando, MD and Canellos, George Peter, MD and Chabner, Bruce A., MD and Chanan-Khan, Asher, MD and Cheson, Bruce, MD and Clarkson, Bayard, MD and Cohn, Susan L., MD and Colon-Otero, Gerardo, MD and Cortes, Jorge, MD and Coutre, Steven, MD and Cristofanilli, Massimo, MD and Curran, Walter J., MD and Daley, George Q., MD, PhD and DeAngelo, Daniel J., MD, PhD and Deeg, H. Joachim, MD and Einhorn, Lawrence H., MD and Erba, Harry P., MD, PhD and Esteva, Francisco J., MD, PhD and Estey, Elihu, MD and Fidler, Isaiah J., DVM, PhD and Foran, James, MD and Forman, Stephen, MD and Freireich, Emil, MD and Fuchs, Charles, MD, MPH and George, James N., MD and Gertz, Morie A., MD and Giralt, Sergio, MD and Golomb, Harvey, MD and Greenberg, Peter, MD and Gutterman, Jordan, MD and Handin, Robert I., MD and Hellman, Samuel, MD and Hoff, Paulo Marcelo, MD and Hoffman, Ronald, MD and Hong, Waun Ki, MD and Horowitz, Mary, MD, MS and Hortobagyi, Gabriel N., MD and Hudis, Clifford, MD and Issa, Jean Pierre, MD and Johnson, Bruce Evan, MD and Kantoff, Philip W., MD and Kaushansky, Kenneth, MD and Khayat, David, MD, PhD and Khuri, Fadlo R., MD and Kipps, Thomas J., MD, PhD and Kripke, Margaret, PhD and Kyle, Robert A., MD and Larson, Richard A., MD and Lawrence, Theodore S., MD, PhD and Levine, Ross, MD and Link, Michael P., MD and Lippman, Scott M., MD and Lonial, Sagar, MD and Lyman, Gary H., MD, MPH and Markman, Maurie, MD and Mendelsohn, John, MD and Meropol, Neal J., MD and Messinger, Yoav, MD and Mulvey, Therese M., MD and O’Brien, Susan, MD and Perez-Soler, Roman, MD and Pollock, Raphael, MD, PhD and Prchal, Josef, MD and Press, Oliver, MD, PhD and Radich, Jerald, MD and Rai, Kanti, MD and Rosenberg, Saul A., MD and Rowe, Jacob M., MD and Rugo, Hope, MD and Runowicz, Carolyn D., MD and Sandmaier, Brenda M., MD and Saven, Alan, MD and Schafer, Andrew I., MD and Schiffer, Charles, MD and Sekeres, Mikkael A., MD, MS and Silver, Richard T., MD and Siu, Lillian L., MD and Steensma, David P., MD and ...
Mayo Clinic Proceedings, ISSN 0025-6196, 2015, Volume 90, Issue 8, pp. 996 - 1000
Internal Medicine | MEDICINE, GENERAL & INTERNAL | Drug Costs | United States - epidemiology | Neoplasms - economics | Humans | Patient Participation | Patient Advocacy | Antineoplastic Agents - economics | Neoplasms - epidemiology | Prescription Fees | Neoplasms - drug therapy | Antimitotic agents | Cancer patients | Patient outcomes | Economic aspects | Dosage and administration | Drug therapy | Antineoplastic agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Allogeneic hematopoietic cell transplantation for myelodysplastic syndromes: Where are we going with this?
by Giralt, Sergio
Journal of Oncology Practice, ISSN 1554-7477, 09/2016, Volume 12, Issue 9, pp. 793 - 794
ONCOLOGY | Myelodysplastic Syndromes | Hematopoietic Stem Cell Transplantation | Transplantation Conditioning | Humans
Journal Article
Details down arrow
15. Full Text 200 mg/[m.sup.2] melphalan--the gold standard for multiple myeloma
by Giralt, Sergio
Nature Reviews Clinical Oncology, ISSN 1759-4774, 09/2010, Volume 7, Issue 9, p. 490
Patient outcomes | Melphalan | Multiple myeloma | Dosage and administration | Research | Drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Defining the Intensity of Conditioning Regimens: Working Definitions
by Bacigalupo, Andrea, M.D and Ballen, Karen, M.D and Rizzo, Doug, M.D and Giralt, Sergio, M.D and Lazarus, Hillard, M.D and Ho, Vincent, M.D and Apperley, Jane, M.D and Slavin, Shimon, M.D and Pasquini, Marcelo, M.D and Sandmaier, Brenda M., M.D and Barrett, John, M.D and Blaise, Didier, M.D and Lowski, Robert, M.D and Horowitz, Mary, M.D
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2009, Volume 15, Issue 12, pp. 1628 - 1633
Defining conditioning regimen intensity has become a critical issue for the hemopoietic stem cell transplant (HSCT) community. In the present report we propose... 
Hematology, Oncology and Palliative Medicine | Reduced intensity | Myeloablative conditioning | Allogeneic transplantation | Conditioning regimens | TOTAL-BODY IRRADIATION | BONE-MARROW-TRANSPLANTATION | ACUTE MYELOGENOUS LEUKEMIA | ACUTE MYELOID-LEUKEMIA | IMMUNOLOGY | VERSUS-HOST-DISEASE | ACUTE MYELOBLASTIC-LEUKEMIA | TRANSPLANTATION | REDUCED-INTENSITY | TERM-FOLLOW-UP | STEM-CELL TRANSPLANTATION | HEMATOLOGY | HEMATOLOGIC MALIGNANCIES | Hematologic Neoplasms - surgery | Humans | Hematologic Neoplasms - drug therapy | Female | Male | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning - methods
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
by McCarthy, Philip L and Owzar, Kouros and Hofmeister, Craig C and Hurd, David D and Hassoun, Hani and Richardson, Paul G and Giralt, Sergio and Stadtmauer, Edward A and Weisdorf, Daniel J and Vij, Ravi and Moreb, Jan S and Callander, Natalie Scott and Van Besien, Koen and Gentile, Teresa and Isola, Luis and Maziarz, Richard T and Gabriel, Don A and Bashey, Asad and Landau, Heather and Martin, Thomas and Qazilbash, Muzaffar H and Levitan, Denise and McClune, Brian and Schlossman, Robert and Hars, Vera and Postiglione, John and Jiang, Chen and Bennett, Elizabeth and Barry, Susan and Bressler, Linda and Kelly, Michael and Seiler, Michele and Rosenbaum, Cara and Hari, Parameswaran and Pasquini, Marcelo C and Horowitz, Mary M and Shea, Thomas C and Devine, Steven M and Anderson, Kenneth C and Linker, Charles
The New England Journal of Medicine, ISSN 0028-4793, 05/2012, Volume 366, Issue 19, pp. 1770 - 1781
In patients who had undergone stem-cell transplantation, lenalidomide maintenance therapy improved progression-free and overall survival, though at the expense... 
INTERGROUPE FRANCOPHONE | MAINTENANCE | MEDICINE, GENERAL & INTERNAL | DEXAMETHASONE | PREDNISONE | RESPONSE CRITERIA | CONSOLIDATION THERAPY | IMPROVES SURVIVAL | THALIDOMIDE | BORTEZOMIB | LEUKEMIA | Thalidomide - adverse effects | Double-Blind Method | Follow-Up Studies | Multiple Myeloma - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Neoplasms, Second Primary - epidemiology | Stem Cell Transplantation | Disease-Free Survival | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Antineoplastic Agents - adverse effects | Adult | Female | Aged | Maintenance Chemotherapy | Thalidomide - therapeutic use | Drugs | Dose-response relationship (Biochemistry) | Care and treatment | Usage | Multiple myeloma | Stem cells | Product/Service Evaluations | Transplantation | Drug therapy | Autografts | Transplants & implants | Toxicity | Clinical trials | Stem cell transplantation | Cancer therapies | Cancer | Hemopoiesis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Stem cell transplantation for multiple myeloma: current and future status
by Giralt, Sergio
Hematology, ISSN 1024-5332, 04/2012, Volume 17, Issue 1, pp. s117 - s120
High-dose melphalan with autologous stem cell support has been an integral part of myeloma therapy for more than 25 years either as salvage therapy or as... 
Stem cell transplantation | Myeloma | STANDARD CHEMOTHERAPY | SINGLE | BONE-MARROW-TRANSPLANTATION | RANDOMIZED-TRIAL | THALIDOMIDE | BORTEZOMIB | INTRAVENOUS MELPHALAN | PLUS DEXAMETHASONE | HIGH-DOSE THERAPY | CONSOLIDATION THERAPY | HEMATOLOGY | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Stem Cell Transplantation - methods | Stem Cell Transplantation - standards | Humans | Induction Chemotherapy | Transplantation, Autologous | Stem Cell Transplantation - trends | Transplantation, Homologous
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome
by Brian L. McClune and Daniel J. Weisdorf and Tanya L. Pedersen and Gisela Tunes da Silva and Martin S. Tallman and Jorge Sierra and John DiPersio and Armand Keating and Robert P. Gale and Biju George and Vikas Gupta and Theresa Hahn and Luis Isola and Madan Jagasia and Hillard Lazarus and David Marks and Richard Maziarz and Edmund K. Waller and Chris Bredeson and Sergio Giralt
Journal of Clinical Oncology, ISSN 0732-183X, 04/2010, Volume 28, Issue 11, pp. 1878 - 1887
Purpose Acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) primarily afflict older individuals. Hematopoietic cell transplantation (HCT) is... 
SURVIVAL | GRAFT-VERSUS-MALIGNANCY | SOUTHWEST-ONCOLOGY-GROUP | ONCOLOGY | ACUTE MYELOGENOUS LEUKEMIA | UNRELATED DONORS | HOST-DISEASE | MARROW-TRANSPLANTATION | CONDITIONING REGIMENS | HEMATOLOGIC MALIGNANCIES | ELDERLY-PATIENTS | Age Factors | Leukemia, Myeloid, Acute - pathology | Humans | Middle Aged | Neoplasm Recurrence, Local - therapy | Hematopoietic Stem Cell Transplantation | Male | Survival Rate | Treatment Outcome | Remission Induction | Transplantation, Homologous | Neoplasm Recurrence, Local - pathology | Adult | Female | Aged | Transplantation Conditioning | Neoplasm Staging | Leukemia, Myeloid, Acute - therapy | Original Reports | Bone1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text ATG and RIC: Not such a good match?
by Giralt, Sergio
Blood, ISSN 0006-4971, 06/2011, Volume 117, Issue 25, pp. 6744 - 6745
PROPHYLAXIS | GLOBULIN | MARROW GRAFTS | UNRELATED DONORS | CELL TRANSPLANTATION | HEMATOLOGY | VERSUS-HOST-DISEASE
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.